Doc Gumshoe, any thoughts on the inhaled insulin that Mannkind MNKD has and is about to be voted on for FDA approval in July. Seems to me that this is a blockbuster grug for a small company that could make the stock take off. Your opinion would be highly appreciated as I’m ready to buy this stock now but am trying to get a better grip on the potential of this drug.
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
Mannkind is not making or bringing anything blockbuster. Yes stock can take off for some time.
But it is not something like BNIKF that is real blockbuster. Dr Kss is talking about BNIKF for 3 months now. That is going to be real winner.
I had asked the same question from Dr kss about mankind. He doesn’t own MNKD.
MNKD can go either way. depends on FDA approval. Can go low as $6.00or as high as $16.00
They’ve a foreign partner now. I’m hoping higher than $20.
I think most of Mannkind’s value lies in the Technosphere platform. I’m not convinced Afrezza will ever gain significant adoption, but I hold a small number of shares because I believe Technosphere could be huge some day, particularly for things like inhaled pain treatment and inhaled erectile dysfunction treatment, if ever pursued.